Jean-Mathieu Beauregard
Chercheur universitaire clinicien
Axe Oncologie
Radiologie, médecine nucléaire et imagerie médicale
Oncologie clinique
Dernières nouvelles
Voir tout
Publications
Voir tout-
article Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É and Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM
Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases t…
Can Urol Assoc J 20 (6), 2026.
-
article Zamanian A, Rousseau É and Buteau FA, Arsenault F, Beaulieu A, April G, Juneau D, Plouznikoff N, Turcotte ÉE, Allard C, Richard PO, Saad F, Guérin B, Pouliot F, Beauregard JM
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
Cancer Imaging 25 (1), 2025.
-
article Akhavanallaf A, Lu Z, Peterson AB, Blakkisrud J, Kurkowska S, Yadav S, Wang C, Uribe C, Stokke C, Rahmim A, Wong KK, Beauregard JM, Hope TA, Sjögreen Gleisner K, Dewaraja YK
Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
J Nucl Med 66 (7), 2025.
Projets
- Tirer profit des données de soins en contexte réel pour une introduction responsable, efficiente et équitable des innovations thérapeutiques en oncologie : la plateforme MEDOnco-VieRéelle, du 2024-09-01 au 2027-08-31
- Enhancing the PARADIM platform to bridge the gap between data and AI in medical imaging, du 2024-09-01 au 2027-08-31
- Les agents theranostiques: anticorps monoclonaux conjugués au médicament et marqués aux radioisotopes 89Zr/225Ac contre le récepteur du facteur de croissance épidermique des cancers colorectal- essai clinique prometteur, du 2024-09-01 au 2027-10-31
- Randomized-controlled, single-blind, pilot study of personalized vs. empiric PSMA-RLT (CAAA617A12102T), du 2025-06-06 au 2030-12-25
- 161Tb/225Ac-labeled anti-Nectin-4 radioimmunoconjugates with/without immune checkpoint inhibitors against NSCLC, du 2025-04-01 au 2030-03-30
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC, du 2025-03-11 au 2028-02-29
- Identifying the subgroups of GEP-NET patients that could benefit from temozolomide-induced upregulation of SSTR2 prior to PRRT, du 2025-06-01 au 2027-05-31
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4-positive NSCLC and TNBC, du 2025-09-26 au 2028-09-25
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC, du 2025-10-01 au 2028-09-30
- Installation centrale d'imagerie moléculaire préclinique, du 2026-03-24 au 2027-09-30
- 4-Timepoint Multi-tracer PET imaging to characterize prOstate Cancer heterogeneity (4TMPO), du 2026-04-01 au 2029-03-31
- Screening of gastroenteropancreatic neuroendocrine tumors from patients for temozolomide-induced upregulation of SSTR2: Towards improved PRRT, du 2023-04-01 au 2025-12-31